Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Terminated × SNX-5422 × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Interventions

Cyclophosphamide 138 Docetaxel 130 Bevacizumab 127 Carboplatin 126 pembrolizumab 124 Gemcitabine 116 Radiotherapy 115 Cisplatin 115 Paclitaxel 112 Capecitabine 101 Rituximab 99 Fluorouracil 93 Oxaliplatin 88 Nivolumab 76 Irinotecan 76 Leucovorin 74 Doxorubicin 71 Dexamethasone 68 Pemetrexed 66 fludarabine 61 Etoposide 60 Bortezomib 57 fludarabine phosphate 56 Erlotinib Hydrochloride 55 Methotrexate 52 Cytarabine 52 Cetuximab 52 Trastuzumab 48 Sorafenib 43 Lenalidomide 43

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02612285 2018-11-14

Study of SNX-5422 in TP53 Null Cancers

Esanex Inc.

Phase 2 Terminated

1 enrolled 3 charts

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡